首页AutophagyCDK
CDK
T1778 AT 7519 hydrochloride salt AT7519 hydrochloride is a multi-CDK inhibitor for CDK1, 2, 4, 6 and 9.
T1785 Palbociclib Palbociclib is an orally available cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. Palbociclib selectively inhibits cyclin-dependent kinase 4 (CDK4)
T1830 BX795 BX795 is an effective and selective PDK1 inhibitor (IC50: 6 nM), and its selectivity is 140- and 1600-fold for PDK1 over PKA and PKC in cell-free assays, respectively. Meanwhile, t
T1837 BX912 BX-912 is a specific inhibitor of 3-Phosphoinositide-dependent Kinase-1 (PDK1, IC50: 12 nM). The selectivity of BX-912 is more 10 fold than C-Kit, EGFR, PKA, PKC etc.
T1855 ZCL 278 ZCL278 is a selective Cdc42 GTPase inhibitor.
T1912 Dinaciclib Dinaciclib is a new-type and effective CDK inhibitor for CDK2/5/1/9 (IC50: 1 nM/1 nM/3 nM/4 nM) with potential antineoplastic activity.
T1917 6-BIO BIO is a specific inhibitor of GSK-3.
T1947 BS181 BS-181 is a highly selective CDK7 inhibitor (IC50: 21 nM); >40-fold selective for CDK7 than CDK1/2/4/5/6/9.
T2028 NG52 NG 52 is a cell-permeable, reversible, and ATP-compatible inhibitor of the cell cycle-regulating kinase Cdc28p and the related Pho85p kinase.
T2029 Bohemine Bohemine is a cyclin-dependent kinase inhibitor.
T2032 WHI-P180 WHI-P180 is a potent EGFR and Cdk2 inhibitors with IC50 of 4.0 and 1.0 uM, respectively.
T2059 Purvalanol A Purvalanol A is an effective and cell-permeable CDK inhibitor with IC50 of 70/4/35/850 nM for cdk2-cyclin A/B/E, and cdk4-cyclin D1, respectively.
T2082 CDK4-IN-1 CDK4 inhibitor is a novel and specific CDK4/Cyclin D1 inhibitor with an IC50 of 10 nM; 1500 and 500 fold than CDK1/Cyclin B (IC50>15 uM) and CDK2/Cyclin A (IC50=5.265 uM) respectiv
T2095 Roscovitine Roscovitine is a potent inhibitor of Cdk2/cyclin E (IC50: 0.1 µM). It also inhibits Cdk7/cyclin H, Cdk5/p35, and Cdc2/cyclin B (IC50s: 0.49/0.16/0.65 µM).
T2113 PHA793887 PHA-793887 has been used in trials studying the treatment of Advanced/Metastatic Solid Tumors.
T2118 SC514 SC-514 is a selective, orally active, ATP-competitive IKK-2 inhibitor (IC50=11.2±4.7 μM), obstructs NF-κB-dependent gene expression.
T2153 1 nM-PP1 1 nM-PP1 is a cell-permeable PP1 analog that acts as a potent and selective inhibitor of mutant kinases over their wild-type progenitors.
T2193 2-Chloropyrazine 2-Chloropyrazine is used in chemical industry.
T2246 LRRK2-IN-1 LRRK2-IN-1 is an effective and selective LRRK2 inhibitor.
T2247 KenPaullone Kenpaullone, a potent CDK1, CDK2 and CDK5 inhibitor, as new enhancer for iTreg cell differentiation. Kenpaullone promotes iTreg cell differentiation through increased and prolonged
T2356 Ro 3306 RO-3306 is a selectivity ATP-competitive CDK1 inhibitor (Ki: 20 nM). The selectivity of RO-3306 for CDK1 is >15-fold higher than a diverse panel of human kinases.
T2378 RGB-286638 free base RGB-286638 free base is a novel CDK inhibitor with IC50s of 1 nM/2 nM/3 nM/4 nM/5 nM for cyclin T1-CDK9/cyclin B1-CDK1/cyclin E-CDK2/cyclin D1-CDK4/cyclin E-CDK3/p35-CDK5 respectiv
T2381 Abemaciclib LY2835219 is an effective and specific CDK4/6 inhibitor (IC50: 2/10 nM).
T2440 IC261 IC261 is a novel inhibitor of CK1, triggers the mitotic checkpoint control. The IC50 of IC261 for CK1 was 16 μM and for Cdk5 is 4.5 mM.
T2463 ML141 ML141 is an effective, specific and reversible non-competitive inhibitor of Rho family GTPase cdc42 (IC50: 200 nM).
T2465 PF562271 PF-562271 is an effective ATP-competitive, reversible inhibitor of FAK(IC50=1.5 nM) and Pyk2 kinase(IC50=13 nM).
T2506 AZD5438 AZD5438 is an effective inhibitor of CDK, for CDK1(IC50=16 nM), CDK2(IC50=6 nM), CDK9(IC50=20 nM).
T2517 SCH900776 CHK1 Inhibitor MK-8776 is an agent targeting cell cycle checkpoint kinase 1 (Chk1) with potential radiosensitization and chemosensitization activities.
T2615 Flavopiridol hydrochloride Alvocidib Hydrochloride is a synthetic N-methylpiperidinyl chlorophenyl flavone compound. As an inhibitor of cyclin-dependent kinase, alvocidib induces cell cycle arrest by prevent
T2670 ML167 ML167 is a highly selective Cdc2-like kinase 4 (Clk4) inhibitor.
T2679 BMS265246 BMS-265246 is a potent and selective CDK1/2 inhibitor.
T2695 TBB TBB(NSC 231634) is a highly selective, ATP/GTP-competitive inhibitor of casein kinase-2 (CK2).
T2709 TAK901 TAK-901 has been used in trials studying the treatment of Lymphoma, Myelofibrosis, Multiple Myeloma, Myeloid Metaplasia, and Advanced Solid Tumors, among others.
T3111 LY2835219 LY2835219 is a specific and effective inhibitor of CDK4(IC50=2 nM) and CDK6(IC50=10 nM).
T3166 VX-11e VX-11e is a potent, selective, and orally bioavailable ERK(Extracellular Signal-Regulated Kinase) inhibitor; antitumor agent.
T3186 NU2058 NU2058 is a guanine-based CDK inhibitor, also inhibits DNA topoisomerase II ATPase activity.
T3195 CVT313 CVT-313(NG-26) is a potent, selective, reversible, and ATP-competitive inhibitor.
T3207 Briciclib Briciclib is a small molecule that suppresses cyclin D1 accumulation in Y cells.
T3352 XL413 XL-413 is an orally bioavailable cell division cycle 7 homolog (CDC7) kinase inhibitor with potential antineoplastic activity. XL-413 binds to and inhibits the activity of CDC7, wh
T3589 NSC23005 Sodium NSC23005 sodium is a novel and effective p18 inhibitor (ED50=5.21 nM) in promoting Hematopoietic stem cells (HSCs) expansion in both murine and human models.
T3590 NSC23005 NSC23005 sodium is a p18INK inhibitor with potently promoted hematopoietic stem cell (HSC) expansion (ED50: 5.21 nM).
T3664 THZ1 THZ1 is a novel selective and potent covalent CDK7 inhibitor.
T3700 SCH900776 S-isomer SCH900776 (S-isomer) is an effective, specific and orally bioavailable inhibitor of checkpoint kinase Chk1 (IC50: 3 nM). It also inhibitors Chk2 (IC50: 1500 nM) and cyclin-dependen
T4227 SB1317 hydrochloride (1204918-72-8(free base)) SB1317 is an effective inhibitor of CDK2/JAK2/FLT3 (IC50: 13/73/56 nM).
T6049 SNS032 SNS-032 is a selective inhibitor of CDK2 (IC50: 48 nM ) and is 10- and 20-fold selective over CDK1/CDK4. It is also sensitive to CDK7/9 (IC50: 62 nM/4 nM), and no effect on CDK6.
T6052 GW 441756 GW 441756 is a specific Tropomyosin-related kinase A (TrkA) inhibitor with an IC50 value of 2 nM.
T6057 URMC099 URMC-099 is an orally bioavailable, brain penetrant MLK inhibitor (IC50: 19/42/14/150 nM, for MLK1/MLK2/MLK3/DLK), and also inhibits LRRK2 activity (IC50: 11 nM).
T6081 Milciclib Milciclib (PHA-848125) is a potent, ATP-competitive CDK inhibitor for CDK2 with IC50 of 45 nM. It is >3-fold more selective for CDK2 than CDK1, 2, 4, 5, and 7. Phase 2.
T6126 JNJ7706621 JNJ-7706621 is a potent aurora kinase inhibitor, and also inhibits CDK1 and CDK2.
T6139 A674563 A-674563 is an Akt1 inhibitor with Ki of 11 nM, modest potent to PKA and >30-fold selective for Akt1 over PKC.
T6154 SU11274 SU11274(IC50=10 nM) is a specific Met inhibitor. It shows no significant effects on PGDFRβ, EGFR or Tie2.
T6162 BS-181 HCl BS-181 HCl is a highly selective CDK7 inhibitor with IC50 of 21 nM. It is more than 40-fold selective for CDK7 than CDK1, 2, 4, 5, 6, or 9.
T6167 SU9516 SU9516 is a potent CDK2 inhibitor, with an IC50 of 22 nM, and also has inhibitory effects on CDK1 and CDK4, with IC50s of 40 nM and 200 nM, respectively.
T6169 Indirubin Indirubin is a potent cyclin-dependent kinases and GSK-3β inhibitor with IC50 of about 5 uM and 0.6 uM.
T6177 PF-562271 besylate PF-562271 (besylate) is a potent, ATP-competitive, reversible inhibitor of FAK with IC50 of 1.5 nM, ~10-fold less potent for Pyk2 than FAK and >100-fold selectivity against other p
T6199 Ribociclib LEE011 is an orally available, and highly specific CDK4/6 inhibitor (IC50:10/39 nM).
T6205 AT7519 AT7519 is a CDK1/2/4/6/9 inhibitor (IC50: 10-210 nM). It is less effective to CDK3 and little active to CDK7.
T6206 PHA767491 PHA-767491 is a potent ATP-competitive dual Cdc7/CDK9 inhibitor with IC50 of 10 nM and 34 nM, respectively.
T6223 U0126-EtOH U0126-EtOH is a non-ATP competitive specific inhibitor of MEK1/2 (IC50: 0.07/0.06 μM).
T6239 Palbociclib hydrochloride Palbociclib (PD-0332991) is a selective inhibitor of CDK4/6 (IC50s: 11/16 nM). It exhibits no inhibition against a panel of 36 additional protein kinases.
T6240 Palbociclib Isethionate Palbociclib (PD-0332991) is a selective inhibitor of CDK4/6 (IC50s: 11/16 nM). It exhibits no inhibition against a panel of 36 additional protein kinases.
T6255 Bromosporine Bromosporine is a broad spectrum inhibitor for bromodomains for BRD2/4/9 and CECR2 (IC50: 0.41/0.29/0.122/0.017 μM), respectively.
T6312 R547 R547 is a potent ATP-competitive inhibitor of CDK1/2/4 with Ki of 2 nM/3 nM/1 nM. It is less potent to CDK7 and GSK3α/β, while inactive to other kinases. Phase 1.
T6458 CYC116 CYC116 is a potent inhibitor of Aurora A/B with Ki of 8.0 nM/9.2 nM, is less potent to VEGFR2 (Ki of 44 nM), with 50-fold greater potency than CDKs, not active against PKA, Akt/PKB
T6563 LDC000067 LDC000067 is a highly specific and selective CDK9 inhibitor with an IC50 value of 44±10 nM.
T6612 NU6027 NU6027 is a potent ATR/CDK inhibitor, inhibits CDK1/2, ATR and DNA-PK with Ki of 2.5 μM/1.3 μM, 0.4 μM and 2.2 μM, enter cells more readily than the 6-aminopurine-based inhibit
T6735 XL413 hydrochloride XL-413 is an orally bioavailable cell division cycle 7 homolog (CDC7) kinase inhibitor with potential antineoplastic activity. CDC7 kinase inhibitor BMS-863233 binds to and inhibit
T6756 AMG 925 AMG 925 is a potent and orally bioavailable dual FLT3/CDK4 inhibitor with IC50 of 1 nM and 3 nM, respectively.
T6786 BI9564 BI-9564, a specific cell-permeable BRD9 BD inhibitor. The Kd for BRD9 is 5.9 nM, and IC50 for BET family is > 100 μM.
T6837 Flavopiridol Flavopiridol (Alvocidib) competes with ATP to inhibit CDKs including CDK1, CDK2, CDK4 and CDK6 with IC50 of ~ 40 nM. It is 7.5-fold more selective for CDK1, 2, 4, 6 versus CDK7. Fl
T6866 K03861 K03861 is a type II CDK2 inhibitor with Kd of 50 nM, 18.6 nM, 15.4 nM, and 9.7 nM for CDK2(WT), CDK2(C118L), CDK2(A144C), and CDK2(C118L/A144C), respectlvely.
T6920 ON123300 ON123300 is a potent and multi-targeted kinase inhibitor for CDK4/Ark5/PDGFRβ/FGFR1/RET/Fyn (IC50: 3.9/5/26/26/9.2/11 nM).
T6940 PHA767491 HCl PHA-767491 is an effective ATP-competitive dual Cdc7/CDK9 inhibitor (IC50: 10/34 nM). It has ~20-fold selectivity against GSK3-β and CDK1/2, 50-fold selectivity against CDK5 and M
T4293 THZ531 THZ531 is a covalent inhibitor of both CDK12(IC50=158 nM) and CDK13(IC50=69 nM).
T4417 LDC-4297 HCl (1453834-21-3(free base)) LDC4297 is a potent and selective CDK7 inhibitor with an IC50 of 0.13 nM.
T4321 Indisulam Indisulam is a carbonic anhydrase inibitor and Antitumor CDK inhibitor. Indisulam targets the G1 phase of the cell cycle by depleting cyclin E. inducing p53 and p21, and inhibiting
T4444 A-674563 HCl (552325-73-2(free base)) A-674563 is an orally available, ATP-competitive, and reversible inhibitor of Akt (Ki: 11 nM for Akt1) [1]. It exhibits inhibitory activity against PKA and Cdk2 (IC50: 16/46 nM) bu
T4482 CC671 CC-671 is a dual TTK protein kinase (IC50: 0.005 μM) /CLK2 (IC50: 0.006 μM) inhibitor.
T5200 Indirubin-3'-monoxime Indirubin-3'-oxime is a potent inhibitor of GSK3β (IC50: 22 nM) and also inhibits CDKs ( (IC50s: 100/180/250 nM for Cdk5/p35, Cdk1/cyclin B, Cdk2/cyclin E).
T5405 BI-1347 BI-1347 is a potent, selective inhibitor of CDK8/cyclinC (IC50: 1 nM). It shows tumor growth inhibition in an in vivo xenograft model.
T5395 BSJ-03-123 BSJ-03-123 is a potent, CDK6-selective small-molecule degrader.
T5533 MC180295 MC180295 is a novel potent, highly selective CDK9 inhibitor (IC50: 5 nM), displays >22-fold selectivity over other CDKs.
T5673 Senexin A Senexin A is an effective and selective CDK8 inhibitor that also inhibits CDK19 with Kd values of 0.83 microns and 0.31 microns, respectively.
T7093 Rafoxanide Rafoxanide as a dual CDK4/6 inhibitor for the treatment of skin cancer. Rafoxanide is a salicylanilide used as an anthelmintic. It is used to treat fluke, hookworm and other infest
T7296 THZ2 THZ2, an analog of THZ1, is a potent and selective CDK7 inhibitor(IC50:13.9 nM),with the potential to treat Triple-negative breast cancer (TNBC).
T7167 Purvalanol B Purvalanol B is a CDK inhibitor that inhibits Cdk2/cyclin A, Cdk2/cyclin E, Cdk5/p35, and Cdk2/cyclin B (IC50s = 6, 9, 6, and 6 nM, respectively)
T7698 BS194 BS194 is as a potent cyclin-dependent protein kinases (CDKs) inhibitor.
T7426 ALSTERPAULLONE Alsterpaullone is a Cyclin-Dependent Kinase Inhibitor, Mediated Toxicity in HeLa Cells Through Apoptosis-Inducing Effec
TQ0053 CYC065 CYC065 is an orally available, second-generation ATP-competitive inhibitor of CDK2/CDK9 kinases (IC50s: 5/26 nM).
TQ0060 LY2857785 LY2857785 is a type I competitive and reversible ATP kinase inhibitor against CDK7/CDK8/CDK9 (IC50s: 246 nM/16 nM/11 nM).
TQ0068 NVP-LCQ195 NVP-LCQ195 (AT9311) is a potent inhibitor of CDK1, CDK2, CDK3 and CDK5 (IC50: 1-42 nM).
TQ0078 CDK inhibitor II CDK-IN-2 is a potent and specific CDK9 inhibitor (IC50: <8 nM).
TQ0266 MSC2530818 MSC2530818 is an effective, selective and orally available CDK8 inhibitor (IC50: 2.6 nM).
T7810 LY-3177833 LY-3177833 is an Cdc7 kinase inhibitor (IC50 : 3.3 nM)
T3971 CASIN CASIN is a specific inhibitor of GTPase Cdc42 (IC50: 2 uM).
T5358 Longdaysin Longdaysin is an inhibitor of CK1α and CK1δ (IC50s: 5.6/8.8 µM). It also can inhibit ERK2 (IC50: 52 µM).
T8230 PNU 112455A PNU 112455A is an ATP site competetive inhibitor of CDK2 and CDK5,binds to the ATP site of CDK2 and CDK5 with Kms of 3.6 and 3.2 μM, respectively.
T8325 SR-4835 SR-4835 is a highly selective dual inhibitor of CDK12 and CDK13(CDK12: IC50=99 nM, Kd=98 nM; CDK13: Kd=4.9 nM), which disables triple-negative breast cancer (TNBC) cells
TN1039 Tamarixetin Tamarixetin has vasodilator effects in rat isolated vessels. Tamarixetin has cytotoxic against leukemia cells and in particular P-glycoprotein- overexpressing K562/ADR cells, it in
TN1222 23-epi-26-Deoxyactein 23-epi-26-Deoxyactein has anti-inflammatory activity, it inhibits nitric oxide production by reducing iNOS expression without affecting activity of the enzyme. It also has anti-can
TN1651 Furanodiene Furanodiene has anti-inflammatory and antioxidant activities, it is active against gram-positive bacteria and Candida albicans.
TN1728 Hellebrigenin Hellebrigenin has anti-hepatoma activities, it induces cell cycle arrest and apoptosis in human hepatocellular carcinoma HepG2 cells through inhibition of Akt. Hellebrigenin exhibi
TN1663 Ganoderic acid DM Ganoderic acid DM is an antiandrogenic osteoclastogenesis inhibitor, it especially suppresses the expression of c-Fos and nuclear factor of activated T cells c1 (NFATc1), this supp
TN2080 Pinoresinol Pinoresinol has antiinflammatory, hepatoprotective, and fungicidal activities, it can protect pial microcirculation from I-reperfusion injury, to increase nitric oxide release and
TN1664 Ganoderic acid H Ganoderic acid H is a potent antitumour agent, it mediates its biological effects through the inhibition of transcription factors AP-1 and NF-kappaB, resulting in the down-regulati
T12355 Palbociclib D8 Palbociclib D8 is a deuterium labeled Palbociclib. Palbociclib is a selective and orally active inhibitor of CDK4 and CDK6 (IC50s of 11 and 16 nM, respectively).
T12552 PROTAC CDK2/9 Degrader-1 PROTAC CDK2/9 Degrader-1 is a potent CDK2 and CDK9 dual degrader(DC50 of 62 nM and 33 nM).
T10096 (2S,3R)-Voruciclib (2S,3R)-Voruciclib is the (2S,3R)-enantiomer of Voruciclib. It is an orally active CDK inhibitor.
T10220 Abemaciclib Metabolites M2 Abemaciclib Metabolites M2 is a metabolite of abemaciclib, acts as a potent CDK4 and CDK6 inhibitor (IC50s: 1-3 nM) with anti-cancer activity.
T10898 Samuraciclib hydrochloride Samuraciclib hydrochloride (CT7001 hydrochloride; ICEC0942 hydrochloride) is a potent, selective, ATP competitive and oral active CDK7 inhibitor with IC50 of 41 nM. The selectivity
T8430 Senexin B Senexin B is a potent and selective inhibitor of CDK8/19(CDK8 and CDK19 with Kds of 140 nM and 80 nM).
T8463 PF-06873600 PF-06873600 is a selective and orally bioavailable cyclin-dependent kinase (CDK) inhibitor(CDK2, CDK4 and CDK6 with Ki of 0.09 nM, 0.13 nM and 0.16 nM, respectively), has potential
T14136 AG-024322 AG-024322 is a potent ATP-competitive inhibitor of pan-CDK against cell cycle kinases CDK1, CDK2, and CDK4(Ki values in the 1-3 nM range)
T14367 AZ1495 AZ1495 is an oral active inhibitor of Interleukin-1 receptor associated kinase 4 (IRAK4), with IC50 values of 5 nM and 23 nM for IRAK4 and IRAK1, respectively. Which Shows activity
T10464L Atuveciclib Racemate Atuveciclib is a potent and highly selective, oral P-TEFb/CDK9 inhibitor which supresses CDK9/CycT1 with an IC50 of 13 nM. Atuveciclib Racemate (BAY-1143572 Racemate) is the racema
T12617 (R)​-​CR8 trihydrochloride (R)-CR8 trihydrochloride is a potent inhibitor CDK1/2/5/7/9.
T10382 AS2863619 free base AS2863619 free base enables the conversion of antigen-specific effector/memory T cells into Foxp3+ regulatory T (Treg) cells. It is a potent, orally active CDK8 and CDK19 inhibitor
T10464 Atuveciclib Atuveciclib (BAY-1143572) is a potent and highly selective, oral PTEFb/CDK9 inhibitor. It inhibits CDK9/CycT1 (IC50: 13 nM).
T10465 Atuveciclib S-Enantiomer Atuveciclib (BAY-1143572) S-enantiomer is a potent and selective CDK9 inhibitor (IC50: 16 nM for CDK9/CycT1).
T10436 AZD4573 AZD4573 is an effective and selective CDK9 inhibitor (IC50: <4 nM). It enables transient target engagement for the treatment of hematologic malignancies.
T14778 BRD6989 BRD6989 is an analog of the natural product cortistatin A (dCA). Which inhibits CDK8 and upregulates IL-10. BRD6989 inhibits the kinase activity of recombinant CDK8 or CDK19 comple
T14779 BRD7389 BRD7389 is an inducer of insulin expression in pancreatic α-cells and a specific inhibitor of RSK family kinase (IC50s: 1.5 μM, 2.4 μM, and 1.2 μM for RSK1, RSK2, and RSK3).
T14914 Cdk1/2 Inhibitor III Cdk1/2 Inhibitor III is a selective Cdk1/2 inhibitor (IC50: 2.1 μM for CDK1/cyclin B).
T14915 CDK12-IN-E9 CDK12-IN-E9 is a potent and selective covalent CDK12 inhibitor and non-covalent CDK9 inhibitor while avoiding ABC transporter-mediated efflux. It has a weak binding ability to CDK7
T14916 CDK2-IN-4 CDK2-IN-4 is a potent and selective inhibitor of CDK2 with an IC50 of 44 nM for CDK2/cyclin A. It shows 2,000-fold selectivity over CDK1/cyclin B with IC50 of 86 uM.
T14918 CDK9-IN-2 CDK9-IN-2 is a special CDK9 inhibitor extracted from patent WO/2012131594A1 (compound CDKI(8)) and has an IC50 of 5 nM and 7 nM in A2058 skin cell line (72 hours) and H929 multiple
T14919 CDKI-73 CDKI-73 is a potent CDK9 inhibitor (Ki: 4 nM). It shows selective toxicity to CLL cells(LD50=80 nM) versus normal B cell and normal CD34+ cell(LD50>20 uM).The inhibition of CDK9 in
T14980 CLK-IN-T3 CLK-IN-T3 is a potent inhibitor of CDC-like kinase (CLK) (IC50s: 0.67 nM, 15 nM, and 110 nM for CLK1, CLK2, and CLK3 protein kinases) with anti-cancer activity.
T14990 CDK12-IN-3 CDK12-IN-3 is a selective CDK12 inhibitor (IC50: 491 nM in an enzymatic assay).
T15204 EHT 5372 EHT 5372 is a strong DYRK’s family kinases of inhibitor (IC50s: 0.22, 0.28 nM for DYRK1A and DYRK1B, respectively).
T15335 FN-1501 FN-1501 is a potent FLT3 and CDK inhibitor (IC50s: 2.47, 0.85, 1.96, and 0.28 nM for CDK2/cyclin A, CDK4/cyclin D1, CDK6/cyclin D1 and FLT3, respectively). FN-1501 also has antican
T10744L SEL120-34A HCl SEL120-34A HCl is a selective, orally available and ATP-competitive inhibitor of CDK8(CDK8/CycC and CDK19/CycC with IC50s of 4.4 nM and 10.4 nM , respectively), with antitumor acti
T10744L2 SEL120-34A monohydrochloride SEL120-34A monohydrochloride is an ATP-competitive and selective inhibitor of CDK8(CDK8/CycC and CDK19/CycC complexes with IC50s of 4.4 nM and 10.4 nM, respectively, with a Kd of 3
T13044 SY-1365 SY-1365 is a highly selective covalent CDK7 inhibitor. SY-1365 possesses therapeutic potential in both hematological and solid tumors.
T13058 T025 T025 is a highly potent and orally available inhibitor of Cdc2-like kinase (CLK)(Kds of 4.8, 0.096, 6.5, and 0.61 nM for CLK1, CLK2, CLK3, and CLK4, respectively).
T13153 THZ1-R THZ1-R displays diminished activity for CDK7 inhibition(Kd:142 nM).
T11309 FMF-04-159-2 FMF-04-159-2 inhibits CDK14 and CDK2 with IC50s of 39.6 nM and 256 nM in NanoBRET assay, respectively. FMF-04-159-2 is a covalent CDK14 inhibitor.
T13696 FN-1501-propionic acid FN-1501-propionic acid and a CRBN ligand have been used to design PROTAC CDK2/9 degrader . FN-1501-propionic acid is a CDK2/9 ligand for PROTAC.
T11345 Lerociclib Lerociclib (G1T38) is a potent and selective inhibitor of CDK4/6, with IC50s of 2nM, 1 nM for CDK6/CyclinD3 and CDK4/CyclinD1, respectively.
T11345L Lerociclib dihydrochloride Lerociclib dihydrochloride is a potent and selective inhibitor of CDK4/CDK6, with IC50s of 2 nM and 1 nM for CDK6/CyclinD3 and CDK4/CyclinD1, respectively.
T10546 bio-THZ1 bio-THZ1 is a biotinylated version of THZ1. THZ1 is a selective and irreversibly covalent CDK7 inhibitor (IC50: 3.2 nM).
T10550 Bisindolylmaleimide X hydrochloride Bisindolylmaleimide X hydrochloride (BIM-X hydrochloride) is a potent and selective PKC inhibitor. It is also a potent CDK2 antagonist (IC50: 200 nM).
T10724 Cdc7-IN-1 Cdc7-IN-1 is a highly selective and ATP competitive inhibitor of Cdc7 kinase (IC50: 0.6 nM at 1 mM ATP). It potently inhibits Cdc7 activity in cancer cells and effectively induces
T11632 IIIM-290 IIIM-290 is an oral CDK inhibitor (IC50s: 90 and 94 nM for CDK2/A and CDK9/T1).
T13202 Trilaciclib hydrochloride Trilaciclib hydrochloride is an inhibitor of CDK4/6 (IC50s: 1 nM and 4 nM for CDK4 and CDK6).
T13309 Voruciclib hydrochloride Voruciclib hydrochloride is an orally active and selective inhibitor of CDK (Ki: 0.626 nM-9.1 nM).
T10735 CDK4/6/1 Inhibitor CDK4/6/1 Inhibitor is a CDK4/6 inhibitor (IC50s: 3 and 1 nM).
T10736 CDK4/6-IN-2 CDK4/6-IN-2 is a potent CDK4 and CDK6 inhibitor (IC50s: 2.7 and 16 nM) extracted from patent US20180000819A1 (Compound 1).
T10737 CDK4/6-IN-3 CDK4/6-IN-3 is a brain-penetrant CDK4/CDK6 inhibitor (Kis: <0.3 nM and 2.2 nM) used for the treatment of glioblastoma. It inhibits CDK1 with a Ki of 110 nM.
T10738 CDK4/6-IN-4 CDK4/6-IN-4 is a selective CDK4/6 inhibitor and the active metabolite of Abemaciclib.
T10739 CDK8/19-IN-1 CDK8/19-IN-1 is a selective and oral bioavailable CDK8/19 dual inhibitor (IC50s: 0.46 nM, 0.99 nM, and 270 nM for CDK8, CDK19, and CDK9).
T10740 CDK8-IN-1 CDK8-IN-1 is a selective CDK8 inhibitor (IC50: 3 nM).
T10741 CDK9-IN-1 CDK9-IN-1 is a novel, selective CDK9 inhibitor for the treatment of HIV infection (IC50: 39 nM for CDK9/CycT1).
T10742 CDK9-IN-10 CDK9-IN-10 is a potent CDK9 inhibitor and the ligand for the PROTAC CDK9 degrader-2.
T10743 CDK9-IN-11 CDK9-IN-11 is a potent CDK9 inhibitor and the ligand for the PROTAC CDK9 degrader-1.
T10745 CDK9-IN-7 CDK9-IN-7 is a highly selective and orally active CDK9/cyclin T inhibitor (IC50: 11 nM), which exhibits more potent over other CDKs (CDK4/cyclinD: 148 nM; CDK6/cyclinD: 145 nM).
T10746 CDK9-IN-8 CDK9-IN-8 is a highly potent and selective CDK9 inhibitor (IC50: 12 nM).
T10747 CDK9-IN-9 CDK9-IN-9 is a potent and selective CDK9 inhibitor (IC50: 1.8 nM) with anti-cancer activity. It inhibits CDK2 (IC50: 155 nM).
T10836 CLK1-IN-1 CLK1-IN-1 is a potent and selective inhibitor of the Cdc2-like kinase 1 (CLK1; IC50: 2 nM).
T15730 Ribociclib hydrochloride Ribociclib hydrochloride is a highly specific CDK4/6 inhibitor (IC50: 10 nM and 39 nM, respectively). It is over 1,000-fold less potent against the cyclin B/CDK1 complex.
T15731 Ribociclib succinate hydrate Ribociclib succinate hydrate is a highly specific CDK4/6 inhibitor (IC50s: 10 nM and 39 nM, respectively). It also is over 1,000-fold less potent against the cyclin B/CDK1 complex.
T15732 Ribociclib succinate Ribociclib succinate is a highly specific CDK4/6 inhibitor (IC50: 10 nM and 39 nM, respectively). It also is over 1,000-fold less potent against the cyclin B/CDK1 complex.
T8484 JSH-150 JSH-150 is a highly selective CDK9 inhibitor(IC50 : 1 nM).
T13627 CP-10 CP-10 is a PROTAC with highly selective and remarkable CDK6 degradation (DC50: 2.1 nM). It inhibits the proliferation of several hematopoietic cancer cells including multiple myelo
T13370 YM-46303 YM-46303 is an antagonist of mAChR
T13425 (1S,3R,5R)-PIM447 dihydrochloride (1S,3R,5R)-PIM447 (dihydrochloride) an inhibitor of PIM(IC50 of 0.095 μM for Pim1, 0.522 μM for Pim2 and 0.369 μM for Pim3).
T11655 Indomethacin-D4 Indomethacin-D4 is a deuterium labeled Indomethacin. Indomethacin is a potent and nonselective inhibitor of COX1 and COX2, with IC50s of 18 nM and 26 nM for human COX-1 and COX-2,
T11656 Indoramin D5 Indoramin D5 is a piperidine antiadrenergic agent. Indoramin D5 is deuterium labeled Indoramin.
T11723 JNJ-39758979 dihydrochloride JNJ-39758979 dihydrochloride functionally antagonizes histamine-induced cAMP inhibition with a pA2 of 7.9 in transfected cells. JNJ-39758979 dihydrochloride shows good anti-inflamm
T16038 Men 10376 Men 10376 is a selective antagonist of tachykinin NK-2 receptor. It has a Ki of 4.4 μM for rat small intestine NK-2 receptor.
T16345 NS13001 NS13001 is a potent, selective, orally active allosteric positive modulator of SK channels (small conductance calcium-activated potassium channels). The EC50s are 1.8 and 0.14 μM
T12617L (R)-CR8 (R)-CR8 is a potent and selective CDK inhibitor.
T10744 SEL120-34A SEL120-34A is a selective, orally available, and ATP-competitive CDK8 inhibitor (IC50s: 4.4 nM and 10.4 nM for CDK8/CycC and CDK19/CycC) with antitumor activity.
T16391 ON-013100 ON-013100 is an antineoplastic drug. It also acts as a mitotic inhibitor that could inhibit Cyclin D1 expression.
T16784 Roniciclib Roniciclib is an inhibitor of pan-cyclin dependent kinase (IC50s: 5-25 nM for CDK1, CDK2, CDK3, CDK4, CDK7, and CDK9).
T12642L Simurosertib Simurosertib is a selective and ATP-competitive cell division cycle 7 kinase inhibitor (IC50: <0.3 nM).
T17069 THAL-SNS-032 THAL-SNS-032 is a selective CDK9 degrader PROTAC.
T13202L Trilaciclib Trilaciclib is an inhibitor of CDK4/6 (IC50s: 1 nM and 4 nM for CDK4 and CDK6, respectively).
T17305 CDK8-IN-4 CDK8-IN-4 is an inhibitor of CDK8 (IC50: 0.2 nM).
T14901 CCT-251921 CCT-251921 is a potent, selective, and orally bioavailable CDK8 inhibitor (IC50: 2.3 nM).
T16363 NVP-2 NVP-2 is an effective and selective ATP-competitive cyclin-dependent kinase 9 (CDK9) probe. NVP-2 induces cell apoptosis. NVP-2 inhibits CDK9/CycT activity (IC50: 0.514 nM). NVP-2
TL0017 Aristolactam AIIIa Aristolactam AIIIa is a new type of Plk1 inhibitors, targeting the Polo Box domain (PBD), it has anti-tumor activity. Aristolactam IIIa shows inhibition of platelet aggregation ind
TN3247 7-O-Prenylscopoletin 7-O-Prenylscopoletin and cedrelopsin show high antiproliferative activities against cancer cell lines.
TN3673 Clausine Z Clausine Z exhibits inhibitory activity against cyclin-dependent kinase 5 (CDK5) and shows protective effects on cerebellar granule neurons in vitro.
TN3719 Cristacarpin Cristacarpin exhibits moderate but selective activity towards DNA repair-deficient yeast mutants. It promotes endoplasmic reticulum (ER) stress, leading to sub-lethal reactive oxyg
TN3802 Dehydrodiconiferyl alcohol Dehydrodiconiferyl alcohol shows anti-adipogenic and anti-lipogenic effects in 3T3-L1 cells and primary mouse embryonic fibroblasts. Dehydrodiconiferyl alcohol can modulate the dif
TMA1743 Ergosterol peroxide Ergosterol peroxide is an inhibitor of osteoclast differentiation, which has antiviral, trypanocidal, antitumor, and antiangiogenic actions, it can stimulate Foxo3a activity by inh
TN4263 Isoangustone A Isoangustone A has antitumor activity, it can induce G1 cycle arrest in DU145 human prostate and 4T1 murine mammary cancer cells, it inhibits cell proliferation by targeting PI3K,
TN4394 Kobophenol A Kobophenol A has antimicrobial, and anti-inflammatory activities, it might be a candidate for treatment of inflammatory bone diseases relevant to osteoblast cell death. Kobophenol
TN4411 Lappaol F 1. Lappaol F has antioxidant and antiaging properties, it may promote the C. elegans longevity and stress resistance through a JNK-1-DAF-16 cascade. <br/> 2. Lappaol F has potentia
T8378 AS2863619 AS2863619 is an orally active inhibitor of cyclin-dependent kinase 8 (CDK8) and CDK19 (IC50s of 0.61 nM and 4.28 nM, respectively).
T5S1467 Cucurbitacin E Cucurbitacin E is a natural product isolated from the climbing stem of Cucumic melo L. It significantly suppresses the activity of the cyclin B1/CDC2 complex.Cucurbitacin E has pre
T13467 (±)-BAY-1251152 (±)-BAY-1251152 is a racemic mixture of BAY-1251152. BAY-1251152 is highly selective inhibitor of PTEF/CDK9.
T2933 Wogonin Wogonin is a cell-permeable and orally available flavonoid that displays anti-inflammatory and anticancer properties.
T19831 Sodium Oxamate Sodium Oxamate is an LDH inhibitor. Sodium oxamate (SO) induces G2/M cell cycle arrest via downregulation of the CDK1/cyclin B1 pathway and promotes apoptosis through enhancement
T8866 GW779439X GW779439X is an inhibitor of CDK.
T8819 SU-9516 SU9516 is a selectively potent ATP-competitive inhibitor of CDKs.
T8801 SRI-29329 SRI-29329 is a potent, specific inhibitor of CDC-like kinase (with IC50 of 78 nM, 16 nM and 86 nM for CLK1, CLK2 and CLK4, respectively).
T8796 CAN508 CAN508 is a potent, ATP-competitive CDK9/cyclin T1 inhibitor with an IC50 of 0.35 μM. It is also a competitive inhibitor of Cdk2-cyclin E with respect to ATP, with Ki and IC50 va
T7444 6-(Dimethylamino)purine 6-(Dimethylamino)purine is a serine threonine protein kinase and CDK  inhibitor
T6139L A-674563 2HCl(552325-73-2(fb-2hcl)) A-674563 is an Akt1 inhibitor with Ki of 11 nM, modest potent to PKA and >30-fold selective for Akt1 over PKC.
T8930 CID44216842 CID44216842 is a potent Cdc42-selective guanine nucleotide binding lead inhibitor. The EC50s for Cdc42 WT and Cdc42Q61L mutant are 1.0 and 1.2 μM in GTP binding assay, respective
T22106 MLS-573151 MLS-573151 is a selective inhibitor of GTPase Cdc42(EC50 of 2 μM). It is inactive against other GTPases family members, such as Rab2, Rab7, H-Ras, Rac1, Rac 2 and RhoA wild-type
T16750 Rigosertib Rigosertib is a selective and non-ATP-competitive inhibitor of PLK1 (IC50: 9 nM). Rigosertib is a multi-kinase inhibitor and a selective anti-cancer agent, which induces apoptosis
  • 关注公众号
    - 超值特惠
    - 客户福利
    - 业界动态
    - 实用攻略
陶素的所有产品和服务仅用于科学研究,我们不为任何其他用途提供产品和服务(也不为任何个人提供产品和服务)。